Fig. 3

Chemotherapy treatment increases CDA and TYMP expression in a subset of lung adenocarcinoma cell lines. a Immunoblotting of CDA and TYMP in KRAS mutant cell lines A549, H358 and H441 after schedule-dependent MTA-cisplatin combination therapy (48 h MTA-pretreatment) at different time points. b Immunoblotting of CDA and TYMP in KRAS mutant cells after single MTA, cisplatin, and concurrent combination treatment at different time points. c Increased CDA enzyme activity of A549 cells after MTA and cisplatin combination treatment, two-sided student’s t test (* p < 0.05); d, g Quantification analysis of CDA and TYMP expression in A549 cells after single MTA, cisplatin and concomitant combination treatment compared to untreated control (see Fig. 3b), N = 2, two-sided student’s t test (* p < 0.05, **p < 0.01, ***p < 0.001). e Inmmunoblotting of CDA and TYMP in non-KRAS mutant cell lines PC-9, H1993 and H3122 after schedule-dependent MTA-cisplatin combination therapy (48 h MTA-pretreatment) at different time points; f Immunoblotting of CDA and TYMP in non-KRAS mutant cell lines PC-9, H1993 and H3122 after single MTA, cisplatin and concurrent combination treatment at different time points; h Quantification analysis of CDA expression in PC-9 after single MTA, cisplatin and concurrent combination treatment, N = 2, two-sided student’s t test (* p < 0.05)